GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (XPAR:ALNOV) » Definitions » GF Score

Novacyt (XPAR:ALNOV) GF Score : 54/100 (As of Apr. 30, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Novacyt GF Score?

Novacyt has the GF Score of 54, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 3/10
3. Growth Rank : 5/10
4. GF Value Rank : 0/10
5. Momentum Rank : 6/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Novacyt might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Novacyt's GF Score

For the Medical Devices subindustry, Novacyt's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novacyt's GF Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Novacyt's GF Score distribution charts can be found below:

* The bar in red indicates where Novacyt's GF Score falls into.



Novacyt  (XPAR:ALNOV) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


Novacyt GF Score Related Terms

Thank you for viewing the detailed overview of Novacyt's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Novacyt (XPAR:ALNOV) Business Description

Traded in Other Exchanges
Address
13, Avenue Morane Saulnier, Velizy-Villacoublay, FRA, 78140
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Novacyt (XPAR:ALNOV) Headlines

No Headlines